Cynapsus Announces Addition of Dr. Albert Agro to Parkinson’s Program Team
Marketwire, July 29, 2022
TORONTO – Cynapsus Therapeutics Inc. (“Cynapsus”) (formerly Cannasat Therapeutics Inc.) (CTH: TSX-V) announced today that it has entered into an agreement with Dr. Albert Agro, an international clinical development expert in CNS diseases, for a portion of his time. Dr. Agro will focus on the development of Cynapsus' Parkinson’s program and, subject to further financings in 2010, will join the company as Chief Medical Officer, with a more significant time commitment.
Dr. Agro is currently the President and CEO of HNZ Strategic Holdings, Inc., a boutique consulting firm which provides innovative clinical development services and counselling to pharmaceutical and biotech companies developing treatments for serious disease. Prior to this role, Dr. Agro was Senior Vice President, Drug Development of TransTech Pharma (2007-2009). From 2003 to 2007, he was a Partner at Axon Medical Communications that helped build the Clinical Research arm of the business (2005-2007), as well as Vice President, Medical and Scientific Affairs at Axon (2003-2005). Dr. Agro served as Director, National Medicine, as well as Director, Immunology, Virology and Respiratory Medicine, at Boehringer Ingelheim (2000-2003). Dr. Agro also worked at Bayer Inc., as Associate Director, Cardiopulmonary Medicine (1998-2000).
Dr. Agro completed his Ph.D. from the Department of Medicine at McMaster University in 1995. After a post-doctoral fellowship at the University of Florence in Italy, Dr. Agro accepted an academic position as assistant professor, Department of Pathology and Molecular Medicine at McMaster University in Hamilton, Ontario which he still maintains today.
"We are extremely pleased that Albert has joined our team,” said Anthony Giovinazzo, Cynapsus’ President and Chief Executive Officer. “Albert brings significant clinical development and business experience to the Company, and has a wealth of important contacts in both the pharmaceutical and academic research communities. This addition reflects the Company's ongoing commitment to add knowledge and depth to our scientific team. Albert has specific and significant international experience in Parkinson’s drug development, which will benefit our existing lead drug program, APL 130277, as well as new programs we intend to develop in our pipeline.”
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.
About Cynapsus Therapeutics
Cynapsus is a specialty clinical development pharmaceutical company targeting diseases of the brain. Cynapsus has a lower risk Parkinson’s drug candidate (“APL-130277”), which is a reformulation of an approved drug. APL-130277 is designed to address a much larger moderate to severe patient population, which represents close to 50% of Parkinson’s patients. Cynapsus also has a proprietary formulation technology for cannabinoid drug candidates, which may be used to treat neuropathic pain associated with multiple sclerosis and cancer, as well as for nausea/vomiting and appetite stimulation.
Cynapsus’ strategy is to grow its portfolio of drug candidates through in-licensing and acquisitions, and to advance projects to Phase 2 proof-of-concept clinical studies. Once the drug candidates are sufficiently derisked, Cynapsus intends to out-license the programs to the appropriate pharmaceutical marketing partners for a combination of upfront, milestone, and royalty payments.
More information about Cynapsus (CTH: TSX-V) is available at www.cynapsus.ca.
Contact Information
Cynapsus Therapeutics Inc.
Andrew Williams
COO & CFO
W: (416) 703-2449 (Ext. 253)
F: (416) 703-8752
[email protected]
www.cynapsus.ca
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of applicable Canadian securities legislation. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Cynapsus to be materially different from those expressed or implied by such forward-looking statements, including but not limited to those risks and uncertainties relating to Cynapsus’ business disclosed under the heading “Risk Factors” in Cynapsus' current Annual Information Form and its other filings with the various Canadian securities regulators which are available online at www.sedar.com. Although Cynapsus has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Cynapsus does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.
--30--
